A gel composition is provided, including an alkaloid compound, or a cannabinoid compound, or both an alkaloid compound and a cannabinoid compound; glycerol; a viscosifying agent; a hydrogen-bond crosslinking gelling agent; and an ionic crosslinking gelling agent; and an acid.

Embodiments relate to a method for treatment of a sleep disorder and to compositions comprising tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN), wherein the ratio of THC:CBD:CBN by weight is A:B:C where A is between 0.0001 and 1, B is 1, and C is between 0.05 and 1. Optionally A is between 0.001 and 0.02, B is 1 and C is between 0.2 and 0.7.

The present invention relates to a liquid pharmaceutical composition comprising cytisine, at least one inorganic pH-regulating agent selected from the group consisting of inorganic acids, inorganic buffers, and inorganic acid salts, and water, wherein the liquid pharmaceutical composition has a pH value between 3.0 and 7.5. The present invention furthermore relates to the liquid harmaceutical composition for use in the treatment of tobacco smoking addiction and other forms of nicotine addiction. Additionally, the invention relates to a liquid pharmaceutical composition comprising cytisine for oral use in the treatment of tobacco smoking addiction and other forms of nicotine addiction.

An inhaler (10) for the inhalation of inhalable substances comprise: a canister (50) having an interior reservoir (84) containing pressurised inhalable substances including fluid; a metering valve (52) including a metering chamber (82) and a valve stem (54) defining a communication path between the metering chamber and the interior reservoir, the communication path (86) including an opening (106) configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for orientation above the metering chamber whereby gas such as air located within the metering chamber is replaced with liquid from the interior reservoir.

Methods and utensils are provided for administering plant extract(s) at controlled amount via smoking, as well as for providing complexes of honey and plant extracts. Plant extract(s) may be used in utensils that are inserted into a smoking appliance, and have indications of the compounds and/or characteristics of the plant extract. Upon smoking the smoking appliance, the plant extracts may be inhaled in pre-defined amounts. Using plant extracts in such way enables standardization of amounts and components thereof, and may be particularly applicable to cannabis oils. Furthermore, complexes of honey and plant extracts may be provided by letting bees step on or be soiled by plant extracts on their way into the beehive, causing them to incorporate the plant extracts into the honey preparation process. Resulting complexes may be a preferable and particularly beneficial way of administering plant extracts, e.g., cannabis extracts.

This invention relates to novel products of Cannabis flower for medicinal and/or recreational use, and for methods of making such products.

Systems, methods, and other embodiments associated with an aromatherapy delivery garment or a medicinal delivery garment. In one embodiment, the aromatherapy delivery garment includes a garment, a pocket assembly operatively connected to the garment, and an aromatherapy benefit delivery system located within the pocket assembly for providing an aromatherapy benefit to a wearer of the garment. In another embodiment, the medicinal benefit delivery garment includes a garment having at least one opening, a medicinal benefit delivery system located on a wearer of the garment for providing a medicinal benefit to a wearer of the garment, wherein the medicinal benefit delivery system is located within the opening, and a pocket assembly operatively connected to the garment, wherein the pocket assembly is located over the opening and the medicinal benefit delivery system in order to conceal the opening and the medicinal benefit delivery system.

The present invention relates to compositions of spherical microparticles composed of a wall material and at least one cavity that comprises a gas and/or a liquid, which have pores on the surface thereof, wherein the spherical microparticles have a mean particle diameter of 10-600 μm and wherein at least 80% of those microparticles, the particle diameter of which does not deviate from the mean particle diameter of the microparticles of the composition by more than 20%, each have on average at least 10 pores, the diameter of which is in the range from 1/5000 to ⅕ of the mean particle diameter, and, furthermore, the diameter of each of these pores is at least 20 nm, wherein the wall material consists of a composition comprising at least one aliphatic-aromatic polyester, and the wall material has a solubility at 25° C. of at least 50 g/l in dichloromethane, a method for the preparation thereof and also the use thereof.

In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or concurrent induction of PAI-1. These changes contribute to excessive FL-fibroblast proliferation and production of extracellular matrix (ECM), and, therefore, pulmonary fibrosis. These processes are reversed by treating the cells, and treating subjects suffering from idiopathic pulmonary fibrosis (IPF) with the small organic molecule nutlin-3a (NTL) or with a peptide, CSP-4 (SEQ ID NO:1), or variants or derivatives or multimers of this peptide, which increase p53 levels by inhibiting MDM2-mediated degradation of p53 protein. Use of these compounds serves as a new approach to the treatment of IPF, as they restore p53 expression and p53-mediated changes in the uPA-fibrinolytic system in FL-fibroblasts and restrict production and deposition of ECM.

There is provided an aerosolizable gel comprising (a) an active agent; (b) one or more gel forming materials, wherein the one or more gel forming material is at least one phyllosilicate; (c) an aerosol forming material selected from glycerol, propylene glycol and mixtures thereof; and (d) water.